EPS

Home prices see modest gains, but rising incomes and balanced inventory are shifting the power back to homebuyers for the first time since the pandemic.

As Perimeter preps its year-end results, investors are watching if its aggressive diversification can overcome operational hurdles and justify its new shape.

As Liberty Latin America preps its 2025 results, investors watch to see if strong subscriber growth and cost-cutting can sustain momentum in a competitive market.

The industrial giant posted strong 2025 results and a cautious 2026 outlook, banking on its execution strategy and key acquisitions in high-growth markets.

The pet insurance giant swung to a major profit in 2025, but a closer look reveals a complex strategy of focused growth and rising acquisition costs.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Brazil's fintech leader reports a record R$5.2B adjusted net income for 2025, outlining a strategy that pairs AI with human advisors to win the market.

With results expected to beat guidance, all eyes are on Progyny's upcoming earnings as a key indicator for the rapidly expanding corporate family-building industry.

A new report says cutting streaming can get you a home in years. But does this advice ignore a broken housing market? We investigate the real path to a down payment.

Networking giant Belden reports record 2025 revenue and profit while launching a major strategic overhaul to dominate the converging IT and OT markets.

Entergy posts strong 2025 earnings and eyes major growth, driven by a surge in demand from data centers and massive new infrastructure projects.

The insurer's double-digit dividend hike follows a year of record core earnings, rewarding shareholders and showcasing its robust financial health.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

Moody's affirms the Estonian energy giant's Baa3 rating, but a negative outlook signals deep-seated risks from its oil shale legacy and market volatility.

With its Q4 and full-year 2025 earnings release imminent, Ingevity faces investor scrutiny over its recent strategic divestitures and market position.

The defense contractor signals a strategic shift after lost contracts and procurement delays slash its 2027 revenue outlook, even as profits beat expectations.

As OneSpaWorld prepares its Q4 results, all eyes are on the wellness giant as a barometer for luxury travel spending and its tech-driven future.

Terex declared a steady dividend, but the real story is its surging stock and a bold forecast, revealing deep confidence in its strategic direction.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

After a stellar 2025, Corpay is hitting the road for key investor conferences. Can it convince the market its impressive growth is just the beginning?